Olema Pharmaceuticals (OLMA) Change in Accured Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Change in Accured Expenses data on record, last reported at $1.3 million in Q1 2026.

  • On a quarterly basis, Change in Accured Expenses rose 111.59% to $1.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $23.5 million, a 6474.3% increase, with the full-year FY2025 number at $11.0 million, down 1.95% from a year prior.
  • Change in Accured Expenses reached $1.3 million in Q1 2026 per OLMA's latest filing, down from $3.6 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for OLMA hit a ceiling of $12.7 million in Q2 2025 and a floor of -$11.2 million in Q1 2025.
  • A 5-year average of $2.0 million and a median of $2.2 million in 2024 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 2481.42% in 2023, then crashed 2684.16% in 2025.
  • Tracing OLMA's Change in Accured Expenses over 5 years: stood at $3.7 million in 2022, then surged by 38.37% to $5.2 million in 2023, then plummeted by 56.87% to $2.2 million in 2024, then skyrocketed by 62.83% to $3.6 million in 2025, then tumbled by 64.09% to $1.3 million in 2026.
  • Business Quant data shows Change in Accured Expenses for OLMA at $1.3 million in Q1 2026, $3.6 million in Q4 2025, and $5.9 million in Q3 2025.